EZH2 and cancer: Our study demonstrated that combined targeting of NF-κB and EZH2 with CAPE and EPZ-6438 respectively have synergistic suppression of cancer in vitro and in vivo and therefore provides information for devising strategies of Synergistic effect for the treatment of glioblastoma.